IL165119A0 - C-aryl glucoside derivatives and pharmaceutical compositions containing the same - Google Patents

C-aryl glucoside derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL165119A0
IL165119A0 IL16511904A IL16511904A IL165119A0 IL 165119 A0 IL165119 A0 IL 165119A0 IL 16511904 A IL16511904 A IL 16511904A IL 16511904 A IL16511904 A IL 16511904A IL 165119 A0 IL165119 A0 IL 165119A0
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
compositions containing
glucoside derivatives
aryl glucoside
Prior art date
Application number
IL16511904A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29582046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL165119(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL165119A0 publication Critical patent/IL165119A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
IL16511904A 2002-05-20 2004-11-09 C-aryl glucoside derivatives and pharmaceutical compositions containing the same IL165119A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/151,436 US6515117B2 (en) 1999-10-12 2002-05-20 C-aryl glucoside SGLT2 inhibitors and method
PCT/US2003/015591 WO2003099836A1 (fr) 2002-05-20 2003-05-15 C-aryl glucosides en tant qu'inhibiteurs de sglt-2 et methode correspondante

Publications (1)

Publication Number Publication Date
IL165119A0 true IL165119A0 (en) 2005-12-18

Family

ID=29582046

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16511904A IL165119A0 (en) 2002-05-20 2004-11-09 C-aryl glucoside derivatives and pharmaceutical compositions containing the same

Country Status (39)

Country Link
US (1) US6515117B2 (fr)
EP (1) EP1506211B1 (fr)
JP (4) JP5090621B2 (fr)
KR (1) KR101021752B1 (fr)
CN (5) CN102627676B (fr)
AR (1) AR040032A1 (fr)
AT (1) ATE353334T1 (fr)
AU (1) AU2003237886B2 (fr)
BE (2) BE2013C025I2 (fr)
BR (2) BR122017015091B8 (fr)
CA (1) CA2486539C (fr)
CY (3) CY1106465T1 (fr)
DE (1) DE60311649T2 (fr)
DK (1) DK1506211T3 (fr)
ES (1) ES2280759T3 (fr)
FR (2) FR13C0022I2 (fr)
GE (1) GEP20084403B (fr)
HK (2) HK1068214A1 (fr)
HR (1) HRP20041084B1 (fr)
IL (1) IL165119A0 (fr)
IN (1) IN2004DE03573A (fr)
IS (1) IS7529A (fr)
LT (1) LTC1506211I2 (fr)
LU (2) LU92182I2 (fr)
ME (2) MEP13008A (fr)
MX (1) MX249731B (fr)
MY (1) MY142499A (fr)
NO (4) NO329107B1 (fr)
NZ (1) NZ536605A (fr)
PE (1) PE20040760A1 (fr)
PL (1) PL210304B1 (fr)
PT (1) PT1506211E (fr)
RS (1) RS51469B (fr)
RU (4) RU2337916C2 (fr)
SI (1) SI1506211T1 (fr)
TW (1) TWI310770B (fr)
UA (1) UA77306C2 (fr)
WO (1) WO2003099836A1 (fr)
ZA (1) ZA200409295B (fr)

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) * 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
EP1345602B1 (fr) 2000-11-30 2010-07-21 Novodermix International Limited Cicatrisation des lesions
KR100883277B1 (ko) * 2001-02-24 2009-02-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체 및 이의 제조방법
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ATE423559T1 (de) * 2001-04-04 2009-03-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
ES2258141T3 (es) * 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
US20030087843A1 (en) * 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1550668A4 (fr) * 2002-10-04 2008-10-01 Kissei Pharmaceutical Derive de pyrazole, composition medicinale renfermant ce derive, utilisation medicinale de cette composition, et intermediaire entrant dans sa production
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
KR20050090437A (ko) * 2003-01-03 2005-09-13 브리스톨-마이어스 스큅 컴퍼니 Ｃ-아릴 글루코시드 ｓｇｌｔ２ 억제제의 제조 방법
EP1457206A1 (fr) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
BRPI0408140B8 (pt) 2003-03-14 2018-12-11 Astellas Pharma Inc derivado de c-glicosídeo ou seu sal, composição farmacêutica e uso do derivado de c-glicosídeo ou seu sal
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
US8785403B2 (en) * 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EA009768B1 (ru) * 2003-08-01 2008-04-28 Янссен Фармацевтика Нв Замещенные конденсированные гетероциклические с-гликозиды
TW200526678A (en) * 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
AU2004261663A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
KR100778988B1 (ko) * 2003-08-01 2007-11-28 다나베 미츠비시 세이야꾸 가부시키가이샤 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
WO2005011592A2 (fr) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Indazoles-o-glucosides substitues
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005085265A1 (fr) * 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
CA2568640C (fr) * 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004034690A1 (de) * 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (fr) * 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
EP1803729A4 (fr) * 2004-09-29 2008-10-01 Kissei Pharmaceutical Composé hétérocyclique azoté 1-( -d-glycopyranosyl)-3-substitué, préparation thérapeutique contenant ledit composé, et emploi médical dudit composé
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20090036355A1 (en) * 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2314743T3 (es) * 2004-12-16 2009-03-16 Boehringer Ingelheim International Gmbh Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
MY147375A (en) * 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
DE602006004964D1 (de) * 2005-02-10 2009-03-12 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren
WO2006089872A1 (fr) * 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Derives d'(hetero)arylethynyl-benzyd-benzene a substitution glucopyranosyle et leur utilisation en tant que cotransporteur 2 de glucose dependant de sodium (sglt2)
EP1874787B1 (fr) * 2005-04-15 2009-12-30 Boehringer Ingelheim International GmbH Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (fr) * 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
ES2346347T3 (es) * 2005-07-27 2010-10-14 Boehringer Ingelheim International Gmbh Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
CA2617102A1 (fr) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Tetrahydro-1h-pyrido[4,3,b]indoles substitues utilises en tant qu'agonistes et antagonistes des recepteurs de la serotonine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1924571B1 (fr) * 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation
MX2008002457A (es) * 2005-09-08 2008-04-07 Boehringer Ingelheim Int Formas cristalinas de 1-cloro-4-(??-d-clucopiranos-1-il).
AR056195A1 (es) * 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
BRPI0620718A2 (pt) * 2005-10-28 2011-11-22 Takeda Pharmaceutical agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
AU2007216452A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
WO2007143052A1 (fr) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides et thiodigalactosides en tant qu'inhibiteurs de la lectine pa-il de pseudomonas
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
WO2008020011A1 (fr) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Dérivés de cyclopropyl-benzène à substitution glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leur utilisation en tant qu'inhibiteurs de sglt et leur procédé de fabrication
EP2066344B2 (fr) * 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Vaccin combiné du virus de poliomyelite inactivé
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
WO2008044762A1 (fr) 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
EP2086991A1 (fr) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH FORME CRISTALLINE DU 4-(ß-D-GLUCOPYRANOS-1-YL)-1-MÉTHYL-2-[4-((S)-TÉTRAHYDROFURAN-3-YLOXY)BENZYL]-BENZÈNE, PROCÉDÉ POUR LA PRÉPARATION DE CELLE-CI ET UTILISATION DE CELLE-CI POUR PRÉPARER DES MÉDICAMENTS
CN101611032B (zh) * 2006-12-04 2012-07-18 詹森药业有限公司 作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CN101657471B (zh) 2006-12-06 2013-07-03 史密丝克莱恩比彻姆公司 二环化合物及其作为抗糖尿病药的用途
WO2008075736A1 (fr) * 2006-12-21 2008-06-26 Astellas Pharma Inc. Procédé de fabrication d'un dérivé de c-glycoside et intermédiaire de synthèse de celui-ci
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2008109591A1 (fr) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
AU2014201239B2 (en) * 2007-03-22 2016-03-10 Astrazeneca Ab Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR101663324B1 (ko) * 2007-07-26 2016-10-06 렉시컨 파마슈티컬스 인코퍼레이티드 나트륨 글루코스 공-전달체 2 억제제의 제조에 유용한 방법 및 화합물
CL2008002425A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
ES2654894T3 (es) * 2007-08-23 2018-02-15 Theracos Sub, Llc Derivados de (2S,3R,4R,5S,6R)-2-(4-cloro-3-bencilfenil)-6-(hidroximetil)tetrahidro-2H-piran-3,4,5-triol para su uso en el tratamiento de diabetes
PT2200606T (pt) * 2007-09-10 2017-12-13 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
PE20091211A1 (es) * 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CN104387354A (zh) * 2007-12-27 2015-03-04 阿斯利康公司 Sglt2 抑制剂的晶体结构及其制备方法
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101969944B (zh) * 2008-01-31 2013-04-10 安斯泰来制药有限公司 脂肪性肝病的治疗用医药组合物
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
US8518895B2 (en) 2008-05-22 2013-08-27 Bristol-Myers Squibb Company Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
JP5820269B2 (ja) * 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
WO2009143021A1 (fr) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Procédé pour traiter et prévenir des calculs rénaux à l'aide d'un inhibiteur de sglt2 et composition le contenant
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2730734C (fr) * 2008-07-15 2017-04-25 Theracos, Inc. Composes de 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene deuterates presentant une activite inhibitrice de cotransporteur sodium-glucose
CA2730603C (fr) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
JP5906086B2 (ja) * 2008-08-15 2016-04-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患の治療に用いるためのプリン誘導体
KR101654231B1 (ko) * 2008-08-22 2016-09-05 테라코스 서브, 엘엘씨 Ｓｇｌｔ２ 억제제의 제조방법
AU2009286380B2 (en) * 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2010026214A1 (fr) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
CN102159561A (zh) * 2008-09-19 2011-08-17 诺瓦提斯公司 糖苷衍生物及其用途
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010045656A2 (fr) * 2008-10-17 2010-04-22 Nectid, Inc. Nouvelles formes posologiques d'inhibiteur sglt2
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MY161472A (en) 2009-02-13 2017-04-14 Boehringer Ingelheim Int Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
LT2395983T (lt) * 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
WO2010092126A1 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant des dérivés de glucopyranosyl diphényl-méthane, sa forme posologique galénique, son procédé de préparation et ses utilisations pour une régulation glycémique améliorée chez un patient
US8466113B2 (en) * 2009-02-23 2013-06-18 Taisho Pharmaceutical Co., Ltd. 4-isopropylphenyl glucitol compounds as SGLT1 inhibitors
EP2226076A1 (fr) 2009-02-25 2010-09-08 Henning Vollert Support d'enregistrement thermosensible et procédé d'enregistrement
AP2011005819A0 (en) * 2009-03-31 2011-08-31 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators.
EP2435033A1 (fr) * 2009-05-27 2012-04-04 Bristol-Myers Squibb Company Méthodes pour le traitement de diabète de type 2 chez des patients résistant à un traitement précédent avec d'autres médicaments anti-diabétiques employant un inhibiteur sglt2 et compositions associées
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010270202B2 (en) 2009-07-10 2014-04-24 Janssen Pharmaceutica Nv Crystallisation process for 1-(beta-D-glucopyranosyl)-4-methyl-3- [5-(4-fluorophenyl)-2-thienylmethyl] benzene
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
DK2486029T3 (en) * 2009-09-30 2015-08-24 Boehringer Ingelheim Int Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
CA2775961C (fr) * 2009-09-30 2017-11-07 Boehringer Ingelheim International Gmbh Procede de preparation d'une forme cristalline de 1-chloro-4-(beta-d-gluucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
RS55909B1 (sr) * 2009-10-14 2017-09-29 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
AU2010310956B2 (en) 2009-11-02 2014-05-08 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
EP2498759B1 (fr) 2009-11-13 2018-08-01 AstraZeneca AB Formulations pour comprimés à libération immédiate
RU2712757C3 (ru) 2009-11-13 2021-06-09 Астразенека Аб Композиция двухслойной таблетки
WO2011058193A1 (fr) 2009-11-16 2011-05-19 Mellitech Dérivés de [1,5]-diazocine
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2011070592A2 (fr) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Nouveaux dérivés de sucres
CN102134226B (zh) * 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011120923A1 (fr) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Composition pharmaceutique comprenant un inhibiteur sglt2 et un agoniste ppar-gamma, utilisations correspondantes
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
TWI564034B (zh) 2010-05-11 2017-01-01 田邊三菱製藥股份有限公司 含１－（β－D－葡萄吡喃糖苷）－３－（苯基噻吩基甲基）苯化合物之錠劑
CN102883726A (zh) 2010-05-11 2013-01-16 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物作为SGLT抑制剂的药物制剂
WO2011153712A1 (fr) 2010-06-12 2011-12-15 Theracos, Inc. Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
WO2012025857A1 (fr) 2010-08-23 2012-03-01 Hetero Research Foundation Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2)
EP2611442B1 (fr) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Formulations de médicament au moyen d'antioxydants hydrosolubles
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2607480C2 (ru) 2011-02-01 2017-01-10 Бристол-Майерс Сквибб Компани Фармацевтические композиции, содержащие аминосоединение
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN103965176B (zh) 2011-02-18 2016-03-16 凯惠药业(上海)有限公司 一种芳基糖苷类化合物及其制备方法和应用
CN102167715B (zh) * 2011-03-07 2013-04-24 上海惠斯生物科技有限公司 一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
AU2012248061C1 (en) * 2011-04-25 2016-07-14 Beijing Prelude Pharm. Sci. & Tech. Co., Ltd. Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
RU2603769C2 (ru) * 2011-05-26 2016-11-27 Тфшем Семейство арил, гетероарил, о-арил и о-гетероарил карбасахаров
ES2448398T3 (es) 2011-06-03 2014-03-13 Ratiopharm Gmbh Composición farmacéutica que comprende dapagliflozina y ciclodextrina
MX2013014135A (es) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
CA2837232A1 (fr) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Composition pharmaceutique comprenant de la dapagliflozine et de la cyclodextrine
CN102875503B (zh) 2011-06-25 2016-05-25 山东轩竹医药科技有限公司 C-糖苷衍生物
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2731947B1 (fr) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement de la diabète type i et type ii
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
CN103889429B (zh) * 2011-10-31 2016-10-19 台湾神隆股份有限公司 Sglt2抑制剂的结晶和非结晶形式
EP2597090A1 (fr) 2011-11-28 2013-05-29 Sandoz AG Hydrate de dapagliflozine cristalline
SI2794626T1 (en) 2011-12-22 2018-02-28 Glycomimetics, Inc. E-SELECTINE ANTAGONIST COMPOUNDS
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2013178064A1 (fr) * 2012-05-29 2013-12-05 广东东阳光药业有限公司 Dérivé glucopyranosyle, son procédé de préparation et son application pharmaceutique
EP2679229B1 (fr) 2012-06-30 2019-02-27 BioActive Food GmbH Composition pour le traitement de pathologies hyperglycémiques
BR112015004012A2 (pt) * 2012-08-30 2017-07-04 Taisho Pharmaceutical Co Ltd combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
AU2013355238B2 (en) 2012-12-07 2017-12-14 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (fr) 2013-03-04 2016-05-18 BioActive Food GmbH Composition pour le traitement de pathologies hyperglycémiques
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9573959B2 (en) 2013-03-14 2017-02-21 Msd International Gmbh Methods for preparing SGLT2 inhibitors
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
WO2014178040A1 (fr) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-cristaux de dapagliflozine
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
US20160214953A1 (en) 2013-09-23 2016-07-28 Sun Pharmaceutical Industries Limited Process for the preparation of dapagliflozin
EP3049397A1 (fr) * 2013-09-27 2016-08-03 Sun Pharmaceutical Industries Ltd Procédé de purification de dapagliflozin
JP6450769B2 (ja) 2013-09-27 2019-01-09 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． グルコピラノシル誘導体及びその医薬品における使用
WO2015051484A1 (fr) 2013-10-12 2015-04-16 Theracos, Inc. Préparation de dérivés d'hydroxy-benzylbenzène
WO2015063726A1 (fr) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Procédé de préparation de 4-bromo-1-chloro-2-(4-éthoxybenzyl)benzène
MX2016007856A (es) 2013-12-17 2016-10-07 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales felinos.
WO2015101916A1 (fr) 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Procédé pour la préparation d'empagliflozin
CN104761522B (zh) * 2014-01-03 2017-02-15 山东轩竹医药科技有限公司 光学纯的苄基‑4‑氯苯基的c‑糖苷衍生物
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
KR102414283B1 (ko) 2014-01-23 2022-06-29 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
CN103739581B (zh) * 2014-01-23 2016-11-23 中国药科大学 C-芳基葡萄糖苷sglt2抑制剂
CN104829572B (zh) * 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法
IN2014MU00626A (fr) * 2014-02-21 2015-09-25 Cadila Healthcare Ltd
US20170056365A1 (en) 2014-02-28 2017-03-02 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US20170029398A1 (en) * 2014-03-06 2017-02-02 Srinivasan Thirumalai Rajan Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof
EP3125882B1 (fr) 2014-04-01 2020-05-13 Boehringer Ingelheim Vetmedica GmbH Traitement de troubles métaboliques chez des équidés
CN105001213B (zh) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
US20170135981A1 (en) * 2014-05-16 2017-05-18 Astrazeneca Ab Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
EP2944311A1 (fr) 2014-05-16 2015-11-18 BioActive Food GmbH Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
WO2015198227A1 (fr) 2014-06-23 2015-12-30 Sun Pharmaceutical Industries Limited Co-cristal de dapagliflozin et d'acide citrique
CN106714840A (zh) 2014-09-25 2017-05-24 阿斯利康(瑞典)有限公司 用于治疗肝病的ω‑3脂肪酸和SGLT‑2抑制剂的组合
CN104327027B (zh) * 2014-10-14 2017-04-05 中国药科大学 一类新型c‑芳基葡萄糖苷sglt2抑制剂
CN104478839A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种达格列净的合成方法
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
AU2015355136B2 (en) 2014-12-03 2020-06-25 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
CN105753910A (zh) * 2014-12-16 2016-07-13 康普药业股份有限公司 一种卡格列净中间体的制备方法
CN104529970A (zh) * 2015-01-08 2015-04-22 江苏联环药业股份有限公司 制备达格列净的方法
CN104478957A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104478966A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104530149A (zh) * 2015-01-14 2015-04-22 佛山市赛维斯医药科技有限公司 卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104478959A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478963A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一种含腈基苯s-葡萄糖苷结构的化合物及其用途
CN104478965A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
CN104497070A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
US10508128B2 (en) 2015-02-09 2019-12-17 Indoco Remedies Limited Process for the preparation of SGLT inhibitor compounds
WO2016144862A1 (fr) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
WO2016161995A1 (fr) 2015-04-08 2016-10-13 Zentiva, K.S. Formes solides de dapagliflozine amorphe
US10556877B2 (en) 2015-05-05 2020-02-11 Glenmark Life Sciences Limited Process for preparation of dapagliflozin
CN106317068A (zh) * 2015-06-23 2017-01-11 中国科学院上海药物研究所 一种c,o-螺环芳基糖苷类化合物及其制备和应用
CN104961715B (zh) * 2015-07-10 2017-08-22 浙江美诺华药物化学有限公司 一种达格列净的制备方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
ES2896101T3 (es) 2015-09-15 2022-02-23 Laurus Labs Ltd Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
CZ2015729A3 (cs) 2015-10-13 2017-04-26 Zentiva, K.S. Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
CN105218329B (zh) * 2015-10-15 2017-05-03 上海应用技术学院 一种列净类似物中间体及其制备方法
US20170106009A1 (en) 2015-10-15 2017-04-20 Boehringer Ingelheim International Gmbh Methods of treating diseases
US9845303B2 (en) 2015-10-19 2017-12-19 Cadila Healthcare Limited Process for the preparation of dapagliflozin
CN106892929B (zh) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) * 2015-12-28 2016-06-22 南昌大学 一种抗糖尿病化合物及其制备方法和用途
HUE051212T2 (hu) * 2016-01-04 2021-03-01 Jeil Pharmaceutical Co Ltd Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció
WO2017118945A1 (fr) 2016-01-08 2017-07-13 Lupin Limited Prémélange de dapagliflozine et son procédé de préparation
US11045485B2 (en) 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
US9834533B2 (en) * 2016-02-19 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing SGLT2 inhibitors and intermediates thereof
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
EP3435987A1 (fr) 2016-03-31 2019-02-06 Lupin Limited Composition pharmaceutique de dapagliflozine
CN107304194A (zh) * 2016-04-20 2017-10-31 扬子江药业集团上海海尼药业有限公司 制备达格列净的方法
EP3466939B1 (fr) * 2016-05-24 2021-02-24 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Nouvelle forme cristalline de la dapagliflozine, son procédé de préparation et son utilisation
WO2017203229A1 (fr) 2016-05-27 2017-11-30 Cipla Limited Prémélanges de dapagliflozine
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
EP3497131B1 (fr) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combinaison d'inhibiteurs des points de contrôle des lymphocytes t avec des inhibiteurs de e-sélectine ou de cxcr4, ou avec des inhibiteurs hétérobifonctionnels de e-sélectine et de cxcr4
US11427555B2 (en) * 2016-08-09 2022-08-30 Laurus Labs Limited Processes for preparation of dapagliflozin or its solvates or co-crystals thereof
WO2018029264A1 (fr) 2016-08-10 2018-02-15 Amneal Pharmaceuticals Company Gmbh Procédé de préparation de dapagliflozine et de ses intermédiaires
BR112019006642A2 (pt) 2016-10-07 2019-07-02 Glycomimetics Inc antagonistas multiméricos de e-selectina altamente potentes
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
KR20180058510A (ko) 2016-11-24 2018-06-01 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
CN108218928B (zh) * 2016-12-13 2020-06-30 华润双鹤药业股份有限公司 葡萄糖苷的二环衍生物及其制备方法和用途
WO2018142422A1 (fr) * 2017-02-02 2018-08-09 Indoco Remedies Limited Procédé de préparation de dapagliflozine
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
WO2018167589A1 (fr) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Composition pharmaceutique comprenant de la dapagliflozine
EP3606527A1 (fr) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Agoniste de ppar-gamma pour le traitement de la paralysie supranucléaire progressive
CN110869380A (zh) * 2017-05-09 2020-03-06 皮拉马尔企业有限公司 用于制备sglt2抑制剂和其中间体的方法
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
WO2019108750A1 (fr) 2017-11-30 2019-06-06 Glycomimetics, Inc. Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
WO2019133878A1 (fr) 2017-12-29 2019-07-04 Glycomimetics, Inc. Inhibiteurs hétérobifonctionnels de e-sélectine et de galectine -3
BR112020018184A2 (pt) 2018-03-05 2021-02-02 Glycomimetics, Inc. usos de compostos
JP2021520394A (ja) 2018-04-17 2021-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、処置方法及びその使用
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
WO2020001812A1 (fr) 2018-06-25 2020-01-02 Pharmathen S.A. Nouveau procédé de préparation d'inhibiteurs de sglt-2
KR20200005320A (ko) 2018-07-06 2020-01-15 한미약품 주식회사 무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
PE20210644A1 (es) * 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN109705075B (zh) * 2018-12-13 2022-12-23 苏中药业集团股份有限公司 一种达格列净的纯化方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP2022530575A (ja) 2019-08-30 2022-06-30 アストラゼネカ・アクチエボラーグ ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
UY38969A (es) * 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
CA3169665A1 (fr) 2020-02-21 2021-08-26 Zaklady Farmaceutyczne Polpharma S.A. Composition pharmaceutique comprenant de la dapagliflozine
EP4114365A1 (fr) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant un inhibiteur du sglt2
CA3173808A1 (fr) 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methodes de traitement de la glomerulosclerose segmentaire et focale dependante de l'apol -1
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
US20230165856A1 (en) 2020-04-29 2023-06-01 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
CN115867538A (zh) 2020-06-05 2023-03-28 新梅斯托克公司 高纯的无定形达格列净的制备
WO2021260617A1 (fr) * 2020-06-25 2021-12-30 Hikal Limited Procédé amélioré de préparation de monohydrate de dapagliflozine-propanediol
BR112023000406A2 (pt) 2020-07-10 2023-01-31 Astrazeneca Ab Combinação de zibotentan e dapagliflozina
WO2022022865A1 (fr) 2020-07-27 2022-02-03 Astrazeneca Ab Procédés de traitement d'une maladie rénale chronique avec de la dapagliflozine
WO2022051316A1 (fr) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Combinaisons à dose fixe de chs-131 et d'un inhibiteur de sglt-2
WO2022067724A1 (fr) 2020-09-30 2022-04-07 北京睿创康泰医药研究院有限公司 Cocristal d'inhibiteur de sglt-2 et de sarcosine, procédé pour sa préparation et utilisation correspondante
WO2022119543A1 (fr) 2020-12-03 2022-06-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine
TR202019590A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
TR202019589A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
TR202019592A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Amorf dapagliflozinin katı farmasötik formülasyonları
EP4315350A1 (fr) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systèmes et méthodes de gestion de prédiabète à l'aide d'une composition pharmaceutique d'inhibiteur de cotransport 2 de sodium-glucose à base de gliflozine
EP4079296A1 (fr) 2021-04-21 2022-10-26 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
WO2023006745A1 (fr) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains
AU2022319909A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
WO2023006747A1 (fr) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies rénales chez des mammifères non humains
CN113773194B (zh) 2021-08-16 2023-05-02 浙江奥翔药业股份有限公司 作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
WO2023129595A1 (fr) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Combinaison d'obicetrapib et d'inhibiteur de sglt2
EP4212150A1 (fr) 2022-01-13 2023-07-19 Sanovel Ilac Sanayi Ve Ticaret A.S. Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
WO2023144722A1 (fr) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2023237512A1 (fr) 2022-06-07 2023-12-14 Astrazeneca Ab Combinaisons de modulateurs de rxfp1 et d'inhibiteurs de sglt2
KR102490653B1 (ko) * 2022-08-03 2023-01-20 진양제약주식회사 다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
KR20240028315A (ko) 2022-08-24 2024-03-05 주식회사 제뉴원사이언스 다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1088346A1 (ru) * 1982-09-28 1986-12-30 Тихоокеанский институт биоорганической химии Дальневосточного научного центра АН СССР Ацетилированные гликозиды 2,5- и 2,8 -дигидрокси-1,4-нафтохинонов,обладающие антигрибковой активностью
JPH03133746A (ja) * 1989-10-19 1991-06-06 Taiyo Kagaku Kogyo Kk 自立袋およびその製造方法
CA2102591C (fr) 1992-11-12 2000-12-26 Kenji Tsujihara Agent hypoglycemiant
EP0671953A4 (fr) * 1992-11-13 1996-01-10 Univ Ohio State Res Found Analogues arylamide de n-(4-hydroxyphenyl)retinamide-o-glucuronide.
US5444050A (en) * 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
ES2176600T3 (es) 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
WO1998031697A1 (fr) 1997-01-15 1998-07-23 Sankyo Company, Limited Composes aryle c-glycoside et esters sulfates de ces derniers
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
IL155066A (en) * 1997-04-04 2004-06-20 Mitsubishi Pharma Corp History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol
JP3451000B2 (ja) 1997-10-20 2003-09-29 新日本製鐵株式会社 方向性珪素鋼板の絶縁皮膜形成方法
DE19806803A1 (de) * 1998-02-18 1999-11-25 Hermann Koepsell Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
ES2258141T3 (es) * 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.

Also Published As

Publication number Publication date
JP5090621B2 (ja) 2012-12-05
RU2643764C2 (ru) 2018-02-05
CN101628905A (zh) 2010-01-20
CN101092409A (zh) 2007-12-26
CN104230866A (zh) 2014-12-24
PE20040760A1 (es) 2004-11-20
AR040032A1 (es) 2005-03-09
RU2337916C2 (ru) 2008-11-10
CN101628905B (zh) 2012-03-21
NO329107B1 (no) 2010-08-23
BRPI0311323B8 (pt) 2021-05-25
KR101021752B1 (ko) 2011-03-15
MXPA04011371A (es) 2005-02-14
RU2746132C3 (ru) 2021-08-02
NO2014017I1 (no) 2014-07-09
LU92182I9 (fr) 2019-01-04
CN1653075A (zh) 2005-08-10
MEP13008A (en) 2010-06-10
CY1106465T1 (el) 2012-01-25
MY142499A (en) 2010-11-30
AU2003237886B2 (en) 2009-02-05
ATE353334T1 (de) 2007-02-15
NO2022041I1 (no) 2022-10-03
NZ536605A (en) 2007-05-31
CY2014025I1 (el) 2015-11-04
CN102627676B (zh) 2014-08-20
CY2013013I1 (el) 2015-11-04
IS7529A (is) 2004-11-16
NO2013007I1 (no) 2013-04-29
LU92496I2 (fr) 2014-09-10
US20020137903A1 (en) 2002-09-26
LU92182I2 (fr) 2013-06-17
RU2013115635A (ru) 2014-10-20
PL210304B1 (pl) 2011-12-30
LTPA2013008I1 (lt) 2013-05-27
AU2003237886A1 (en) 2003-12-12
NO20044915L (no) 2004-12-16
RS99204A (en) 2006-12-15
RU2004137489A (ru) 2005-06-27
ME00091B (fr) 2010-10-10
RS51469B (en) 2011-04-30
ZA200409295B (en) 2006-02-22
HK1205120A1 (en) 2015-12-11
RU2008122558A (ru) 2009-12-20
BR122017015091B1 (pt) 2018-05-15
BR0311323A (pt) 2005-03-15
NO2013007I2 (no) 2013-04-12
PT1506211E (pt) 2007-04-30
IN2004DE03573A (fr) 2005-04-01
EP1506211A4 (fr) 2005-08-17
DK1506211T3 (da) 2007-04-10
CA2486539C (fr) 2012-03-13
CY2013013I2 (el) 2015-11-04
GEP20084403B (en) 2008-06-25
HRP20041084B1 (en) 2008-06-30
FR13C0022I2 (fr) 2014-03-07
SI1506211T1 (sl) 2007-10-31
JP2014028807A (ja) 2014-02-13
ES2280759T3 (es) 2007-09-16
RU2489151C3 (ru) 2019-11-28
UA77306C2 (uk) 2006-11-15
DE60311649T2 (de) 2007-11-22
KR20050004161A (ko) 2005-01-12
MX249731B (es) 2007-10-01
BRPI0311323B1 (pt) 2017-09-26
RU2643764C9 (ru) 2021-12-15
RU2489151C2 (ru) 2013-08-10
DE60311649D1 (de) 2007-03-22
HRP20041084A2 (en) 2005-06-30
RU2017131447A (ru) 2019-03-07
JP5340077B2 (ja) 2013-11-13
JP2009275050A (ja) 2009-11-26
FR14C0054I1 (fr) 2014-08-08
FR13C0022I1 (fr) 2014-02-03
CY2014025I2 (el) 2015-11-04
RU2746132C1 (ru) 2021-04-07
TWI310770B (en) 2009-06-11
CN100534997C (zh) 2009-09-02
HK1068214A1 (en) 2005-04-22
JP5584738B2 (ja) 2014-09-03
JP5604568B2 (ja) 2014-10-08
JP2005531588A (ja) 2005-10-20
PL373369A1 (en) 2005-08-22
CN102627676A (zh) 2012-08-08
EP1506211B1 (fr) 2007-02-07
JP2012207037A (ja) 2012-10-25
WO2003099836A1 (fr) 2003-12-04
CA2486539A1 (fr) 2003-12-04
BR122017015091B8 (pt) 2021-07-27
US6515117B2 (en) 2003-02-04
RU2017131447A3 (fr) 2021-01-14
TW200404813A (en) 2004-04-01
BE2014C041I2 (fr) 2022-08-09
BE2013C025I2 (fr) 2022-09-29
EP1506211A1 (fr) 2005-02-16
LTC1506211I2 (lt) 2023-02-10

Similar Documents

Publication Publication Date Title
IL165119A0 (en) C-aryl glucoside derivatives and pharmaceutical compositions containing the same
IL206831A0 (en) Glucopyranosyl derivatives and pharmaceutical compositions containing the same
IL148806A0 (en) C-aryl glucoside derivatives and pharmaceutical compositions containing the same
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
IL164209A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL166620A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL164987A (en) Proline derivatives and pharmaceutical compositions containing the same
IL241211A0 (en) History of maytansinoid and pharmaceutical preparations containing them
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL166232A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL176005A0 (en) 2,6-bisheteroaryl-4-aminopyrimidine derivatives and pharmaceutical compositions containing the same
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
IL172937A0 (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
IL165388A0 (en) Macrolide compounds and pharmaceutical compositions containing the same
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL158041A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXTF Application for patent extension filed

Filing date: 20141124

PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: DAPAGLIFLOZIN PROPANEDIOL

Extension date: 20261112

KB Patent renewed
EXTG Extension of patent term granted

Extension date: 20251004

KB Patent renewed